A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine (CONQUER)

I5Q-MC-CGAW -

The purpose of this study is to assess the safety and efficacy of galcanezumab in people with treatment-resistant episodic or chronic migraine.

Trial Summary

Age Range
18 - 75 years
Conditions the trial is for
Migraines
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
463
Trial Dates
Jul 31, 2018 - Sep 19, 2019
How long will I be in the trial?
The study will last about 8 months and may include up to 9 visits.
Trial Phase
III

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.